The European Medicines Agency (EMA) launches survey to assess whether patients and doctors are aware of the arrangements for reporting of side effects.
EMA has launched a survey to better understand patients’ and healthcare professionals’ awareness of reporting adverse drug reaction, including for medicines under ‘additional monitoring’. Medicines under additional monitoring are monitored particularly closely by regulatory authorities. They are easily identified by a black inverted triangle displayed in their package leaflet and in the information for healthcare professionals, called the ‘summary of product characteristics’ (SmPC). Healthcare professionals and patients are encouraged to report any suspected adverse reactions.
Regulatory authorities continuously look at reports of side effects alongside all the information they already have to make sure that the benefits of medicines remain greater than their risks and to take any necessary action.
The survey’s main aim is to evaluate the awareness, attitudes and reporting behaviours of patients and healthcare professionals to report side effects. The questionnaire is translated into all official European Union languages and takes no more than 10 minutes to complete. It will be open for responses until 9 October 2017. The results of the survey will be analysed by EMA and the European Commission and the conclusions will be published in 2018.
Russian pharmaceutical company NovaMedica, a portfolio company of RUSNANO, announces the start of construction of a plant for the production of sterile injectable drugs as part of its long-term strategy to localize innovative medicines and technologies of their development and production in Russia. The plant will be built in the industrial park “Vorsino” in the Kaluga region.
22 September 2017
22 September 2017